Durysta (Bimatoprost) Patent Expiration, LOE Window & CMS Spending

Durysta (Bimatoprost) by AbbVie: FDA Orange Book core substance LOE 2031-07-15 (last listed 2034-10-31), 2 AB generics, $2.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN211911 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-07-15
Last Listed Patent or Exclusivity Date2034-10-31
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$2.8M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$1.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.